{
    "clinical_study": {
        "@rank": "168086", 
        "arm_group": {
            "arm_group_label": "ATIR", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ATIR is safe and effective in reducing\n      transplant-related mortality and improving overall survival, when infused in patients with a\n      hematologic malignancy following a T-cell depleted stem cell graft from a related\n      haploidentical donor."
        }, 
        "brief_title": "Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Acute Lymphoblastic Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study CR-AIR-007 is an exploratory, open-label, multicenter study. After signing informed\n      consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a\n      related, haploidentical donor, followed by infusion with ATIR between 28 and 32 days after\n      the HSCT (or later if required by the patient's medical condition). Patients will receive\n      ATIR as a single infusion at a dose of 2x10E6 viable T-cells/kg. All patients treated with\n      ATIR will be followed up until 12 months after the HSCT. Assessments will be performed at\n      weekly visits from the day of ATIR infusion until 8 weeks after ATIR infusion, at monthly\n      visits from 3 until 6 months after the HSCT, every 2 months from 6 until 12 months after the\n      HSCT, and every 6 months from 12 until 24 months after the HSCT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Any of the following hematologic malignancies: a) Acute myeloid leukemia (AML) in\n             first remission with high-risk features or in second or higher remission b) Acute\n             lymphoblastic leukemia (ALL) in first remission with high-risk features or in second\n             or higher remission c) Myelodysplastic syndrome (MDS): transfusion-dependent, or\n             intermediate or higher Revised International Prognostic Scoring System (IPSS-R) risk\n             group\n\n          -  Eligible for haploidentical stem cell transplantation according to the investigator\n\n        Exclusion Criteria:\n\n          -  Availability of a suitable matched related or unrelated donor following a donor\n             search\n\n          -  In second or higher remission with the previous remission having lasted less than 6\n             months\n\n          -  Diffusing capacity for carbon monoxide (DLCO) < 50% predicted\n\n          -  Left ventricular ejection fraction < 50% (evaluated by echocardiogram or multiple\n             gated acquisition [MUGA])\n\n          -  Aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)(CTCAE grade 2)\n\n          -  Bilirubin > 1.5 x ULN (CTCAE grade 2)\n\n          -  Creatinine clearance < 50 mL/min (calculated or measured)\n\n          -  Positive test for human immunodeficiency virus (HIV)\n\n          -  Positive pregnancy test (women of childbearing age only)\n\n          -  Prior allogeneic stem cell transplantation using stem cells from a matched sibling\n             donor, a matched unrelated donor, a haploidentical donor, or a cord blood donor\n\n          -  Prior autologous stem cell transplantation\n\n          -  Stay at intensive care unit for more than 2 months in the preceding 12 months\n\n          -  Estimated probability of surviving less than 3 months\n\n          -  Known allergy to any of the components of ATIR (e.g., dimethyl sulfoxide)\n\n          -  Any other condition which, in the opinion of the investigator, makes the patient\n             ineligible for the study\n\n        Donor inclusion criteria\n\n          -  Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci\n             of the unshared haplotype\n\n          -  Male or female, age \u2265 18 and \u2264 75 years\n\n          -  Eligible for donation according to the transplantation center\n\n        Donor exclusion criteria\n\n          -  Positive viral test for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus\n             (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV)-1*, HTLV-2*, or WNV* (if\n             tested)   (* at Canadian centers only)\n\n          -  Positive pregnancy test or nursing (women of childbearing age only)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794299", 
            "org_study_id": "CR-AIR-007", 
            "secondary_id": [
                "2012-004461-41", 
                "File # 9427-K0980\\1-21C"
            ]
        }, 
        "intervention": {
            "arm_group_label": "ATIR", 
            "description": "Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.", 
            "intervention_name": "ATIR", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Haploidentical stem cell transplantation", 
            "Graft-versus-host disease", 
            "Immune reconstitution", 
            "Alloreactive T-cells", 
            "Photodepletion", 
            "Photodynamic treatment", 
            "TH9402", 
            "Transplant-related mortality", 
            "Hematologic malignancy"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruges", 
                        "country": "Belgium", 
                        "zip": "8000"
                    }, 
                    "name": "Algemeen Ziekenhuis Sint-Jan"
                }, 
                "investigator": {
                    "last_name": "Dominik Selleslag, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Universit\u00e9 Libre de Bruxelles - Institute Jules Bordet"
                }, 
                "investigator": {
                    "last_name": "Philippe Lewalle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louvain", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Universitair Ziekenhuis Gasthuisberg"
                }, 
                "investigator": {
                    "last_name": "Johan Maertens, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 1C3"
                    }, 
                    "name": "Juravinsky Hospital and Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Irwin Walker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }, 
                    "name": "Maisonneuve-Rosemont Hospital"
                }, 
                "investigator": {
                    "last_name": "Denis-Claude Roy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor", 
        "overall_contact": {
            "email": "k.reitsma@kiadis.com", 
            "last_name": "Karen Reitsma", 
            "phone": "+31 20 3140 250"
        }, 
        "overall_official": {
            "affiliation": "Maisonneuve-Rosemont Hospital, Montreal Quebec", 
            "last_name": "Denis-Claude Roy, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Transplant-related mortality (TRM)", 
            "safety_issue": "No", 
            "time_frame": "At 6 months post HSCT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Immune reconstitution", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "TRM", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Relapse-related mortality (RRM)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Incidence of viral, fungal, and bacterial infections", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Severity of viral, fungal, and bacterial infections", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Incidence of acute and chronic graft versus host disease (GvHD)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months post HSCT"
            }, 
            {
                "measure": "Severity of acute and chronic GvHD", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months post HSCT"
            }
        ], 
        "source": "Kiadis Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kiadis Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}